ASH News Daily - Saturday, December 10, 2011 - (Page B-30)

Page B–30 ® ASH NewS DAily The theme of this year’s Junior Faculty Development Program is mentoring. Topics to be addressed include negotiating the transition from fellowship to faculty, including how to establish a “niche,” and how the mentee role changes as one progresses from trainee to attending. The speakers will discuss how to become a good mentor, addressing the challenges of a junior faculty member serving as a mentor and how junior faculty can best support their mentees. Finally, a successful senior mentor will discuss how to identify problems in the mentoring relationship, with advice on how to talk to one’s mentor to remedy these issues and, if necessary, how to transition to a different mentor. Topic 1: Cutting the Apron Strings: How to Become Independent and Develop a Niche Corey Cutler, MD, MPH, Dana-Farber Cancer Institute Topic 2: The Warning Signs of a Problematic Mentoring Relationship and How to Fix It Mary M. Horowitz, MD, MS, Center for International Blood and Marrow Transplant Research and FMLH & MCW Clinical Cancer Center Saturday, December 10, 2011 Trainee Lounge San Diego Convention Center, Sails Pavilion, Upper Level Saturday, Sunday, and Monday: 7:00 a.m. - 6:00 p.m. Tuesday: 7:00 a.m. - 12:00 noon FocuS on earlyFocuS on earlycareer hematologiStS career hematologiStS Trainees «« From Page B-16 Junior Faculty Development Program: Mentorship: How to Receive It, How to Provide It, How to Optimize It Today, 4:00 - 5:30 p.m. San Diego Convention Center, Room 30 Topic 3: Transitioning From Being a Mentee to Becoming a Mentor Stephanie J. Lee, MD, MPH, Fred Hutchinson Cancer Research Center »» TRAINEES Page B-33 Hodgkin lymphoma— ≈10% refractory rates1 ≈ 30% relapse rates after complete response1 ≈ 50% of transplants fail2,3 Long-term health complications4 Reduced survival in some patients initially cured5 NoGoodCancer.com Visit us at ASH booth 129 References 1. Quddus F, Armitage JO. Salvage therapy for Hodgkin’s lymphoma. Cancer J. 2009;15(2):161-163. 2. Sureda A, Constans M, Iriondo A, et al; The Grupo Español de Linfomas/Transplante Autólogo de Médula Osea (GEL/TAMO) Cooperative Group. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol. 2005;16(4):625-633. 3. Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12(10):1065-1072. 4. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21(18):3431-3439. 5. Martinez C, Canals C, Alessandrino E, et al; Lymphoma Working Party of the EBMT. Relapse of Hodgkin’s lymphoma (HL) after autologous stem cell transplantation (ASCT): prognostic factors in 462 patients registered in the database of the EBMT. J Clin Oncol. 2010;28(15)(suppl):8060. Seattle Genetics and are US registered trademarks of Seattle Genetics, Inc. © 2011 Seattle Genetics, Inc., Bothell, WA 98021 All rights reserved US/BVP/2011/0138 003192_sgn35_ngc_and_fa1.indd 1 10/24/11 1:14 PM

Table of Contents for the Digital Edition of ASH News Daily - Saturday, December 10, 2011

ASH News Daily - Saturday, December 10, 2011

https://www.nxtbookmedia.com